Glick S D, Maisonneuve I M, Visker K E, Fritz K A, Bandarage U K, Kuehne M E
Department of Pharmacology and Neuroscience, Albany Medical College, NY 12208, USA.
Psychopharmacology (Berl). 1998 Oct;139(3):274-80. doi: 10.1007/s002130050716.
Two studies were conducted to assess, in vivo, potential anti-nicotinic effects of the iboga alkaloid ibogaine and its synthetic congener 18-methoxycoronaridine (18-MC). As previously demonstrated for ibogaine, using microdialysis, pretreatment (19h beforehand) with 18-MC (40 mg/kg, i.p.) significantly attenuated nicotine-induced dopamine release in the nucleus accumbens of awake and freely moving rats. In an oral model of nicotine self-administration, both ibogaine and 18-MC decreased rats' preferences for nicotine for at least 24 h. Acutely, during the first hour after administration, ibogaine depressed responding for water as well as for nicotine; however, during this same time, 18-MC reduced nicotine intake without affecting responding for water. The results suggest that 18-MC might be the prototype of a new treatment for smoking.
进行了两项研究，以在体内评估伊博格生物碱伊波加因及其合成类似物18-甲氧基柯诺里定（18-MC）的潜在抗烟碱作用。如先前对伊波加因所证明的，使用微透析法，用18-MC（40毫克/千克，腹腔注射）进行预处理（提前19小时）可显著减弱尼古丁诱导的清醒且自由活动大鼠伏隔核中的多巴胺释放。在尼古丁自我给药的口服模型中，伊波加因和18-MC均使大鼠对尼古丁的偏好降低至少24小时。急性给药时，在给药后的第一小时内，伊波加因抑制了对水以及尼古丁的反应；然而，在同一时间内，18-MC减少了尼古丁摄入量，而不影响对水的反应。结果表明，18-MC可能是一种新型戒烟治疗方法的原型。
